Pharmaceutical Process Research Consultant: Synthesis and Process for API, Controlled Substances and Platinum Compounds (1487)

Expertise

  • Synthetic organic chemistry for active pharmaceutical ingredients (API).
  • Pharmaceutical process research, development and scale up.
  • Organic synthesis, including platinum chemistry and synthesis of controlled substances such as cannabinoid, opiod and methamphetamine compounds.
  • Skilled at terpene, heterocyclic, amino acid and organometallic chemistry and asymmetric synthesis.
  • Good manufacturing practice (GMP) for pharmaceuticals.
  • Development of anti tumor compounds.

Experience

Undisclosed Company, 1997 - 2008

Principal Scientist, 2008
  • Conducted pharmaceutical process research and development, including GMP scale up of controlled substances and platinum compounds.
Senior Development Associate, 2000 - 2007
  • Management and leadership duties of chemical process research and development.
  • Project leader for tetrahydrocannibinol (THC), nabilone, dexanabinol, metaxalone, methamphetamine, methyl phenidate, and platinum anticancer drugs oxaliplatin, JM-216 (satraplatin), carboplatin, and cisplatin.
  • Project leader for tetrahydrocannibinol (THC), nabilone, dexanabinol, metaxalone, methamphetamine, methyl phenidate, and platinum anticancer drugs oxaliplatin, JM-216 (satraplatin), carboplatin, and cisplatin.
  • Invented novel syntheses of anti-emetic THC, and demonstrated novel terpene chemistry; successfully validated process in plant, leading to commercializaton.
  • Researched, developed, and successfully scaled process for anti-emetic cannabinoid nabilone; successfully scaled process in GMP laboratory.
  • Researched new synthetic route to cannabinoid drug candidate dexanabinol and demonstrated novel route to cannabinoids.
  • Researched and successfully developed process for benzodiazepine anti-anxiety drug lorazepam.
  • Rapidly discovered and developed new process for muscular relaxant metaxalone; process was validated in the plant and commercialized.
  • Supported ongoing plant operations for carboplatin and cisplatin; improved the carboplatin recrystallization procedure in the plant.
  • Successfully validated a difficult process for platinum anticancer drug candidate JM-216 (satraplatin).
  • Did an extensive cost analysis of approaches to economical synthesis of D-methyl phenidate resulting in new syntheses of racemic and chiral methyl phenidate, drastically reducing cost and cycle versus earlier processes.
  • Discovered and demonstrated new process for methamphetamine.
  • Discovered and demonstrated new process for benzphetamine.
  • Invented and developed a new, very simple process for purification of morphine from concentrated poppy straw (CPS), drastically reducing cost and cycle time from the earlier process. Process was validated in the plant and commercialized.
  • Rapidly discovered and developed a new crystallization procedure for hydrocodone, and discovered new polymorph.
  • Invented new synthesis of oxycodone from 14-hydroxycodeinone.
Stringer, Chemical Engineering Magazine, Chemical Week Associates, New York, NY, 1997 - 2002
  • Wrote, edited articles, consultant to other authors, and gave scientific advice.
Bristol-Myers Squibb Co., Senior Scientist, Syracuse, NY, 1991 - 1996
  • Conducted pharmaceutical process research.
  • Invented, successfully developed and scaled new synthetic routes to the important anti tumor drugs etoposide phosphate and etoposide.
  • Oversaw technology transfer to Swords, Ireland facility.
  • Helped develop the process for the anti-coagulant ifetroban.
  • Worked on processes for the amino acid derivative eflornithine and the ACE/NEP inhibitor omapatrilat.

Honors & Publications

Publications and Patents
  • Ten publications - Publication list available up requests.
  • Six patents

Education

  • Ph.D. Organic Chemistry, University of Delaware, Newark, DE
  • B.S., Chemistry, George Washington University, Washington, DC